AI Science Tracker

AI co-scientist: a multi-agent system for generating hypotheses

Google Research · 19 Feb 2025 · medicine

Discovery

Google Research

AI co-scientist: a multi-agent system for generating hypotheses

A system based on Gemini 2.0 that generates hypotheses and research proposals. In the lab, three drugs it suggested for repurposing against acute myeloid leukemia reduced cancer-cell viability, and all suggested treatments for liver fibrosis showed activity. Expert assessments covered only 11 targets; fibrosis results awaited a Stanford report.

Technology: AI co-scientist (Gemini 2.0, multi-agent)

Family AI Co-Scientist: profile · models page

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: Elo auto-evaluation over 203 research goals; 15 expert-curated goals; blinded experts rated 11 goals (preference rank 2.36). In vitro on four AML cell lines: binimetinib, pacritinib, cerivastatin reduced viability; KIRA6 IC50 10 nM in KG-1a versus 180 nM in TK6. Seven combinations tested.
  • Still unknown: The paper calls validation preliminary and in vitro only. KIRA6 was far less effective in MOLM-13 and HL-60. Expert evaluation was small and subjective; Elo is not ground truth. Liver fibrosis and AMR details are summarized only.
  • AI role: A Gemini-based multi-agent system generated, debated and ranked hypotheses; experts selected candidates and prioritized lab experiments.

Evidence sources: https://doi.org/10.1038/s41586-026-10644-y

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: blog. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open in the full catalog for filters, charts and related discoveries.